In conditions such as sarcoidosis, checkpoint inhibitors, including PD‐1 or CTLA‐4, which are under investigation for cancer therapies‐might control hyperactive immune reactions and deter the development of granulomas. This evidence concerns the gene CTLA4 and cancer.